Sign In
Buy AKBA
$0.97
+0.0333 (+3.56%)
At Close: Jun 03, 2026
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives $6.00 Consensus Price Target from Analysts
01:26am, Monday, 02'nd Feb 2026
Shares of Akebia Therapeutics, Inc. (NASDAQ: AKBA - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven analysts that are covering the stock, Marketbeat Ratings reports. O
Vivos Therapeutics (NASDAQ:VVOS) and Akebia Therapeutics (NASDAQ:AKBA) Head to Head Contrast
06:13am, Tuesday, 20'th Jan 2026
Akebia Therapeutics (NASDAQ: AKBA - Get Free Report) and Vivos Therapeutics (NASDAQ: VVOS - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contras
Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts
01:21pm, Tuesday, 13'th Jan 2026
Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook
08:00am, Monday, 12'th Jan 2026
Positioned to increase depth of Vafseo prescribing entering 2026 with access to approximately 275,000 patients First patient dosed in Praliciguat Phase 2 clinical trial studying focal segmental glomer
CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 05'th Jan 2026
CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
Assenagon Asset Management S.A. Makes New Investment in Akebia Therapeutics, Inc. $AKBA
03:20am, Thursday, 25'th Dec 2025
Assenagon Asset Management S.A. acquired a new stake in shares of Akebia Therapeutics, Inc. (NASDAQ: AKBA) in the third quarter, according to the company in its most recent Form 13F filing with the Se
Comparing NLS Pharmaceutics (NASDAQ:NCEL) & Akebia Therapeutics (NASDAQ:AKBA)
01:40am, Thursday, 04'th Dec 2025
NLS Pharmaceutics (NASDAQ: NCEL - Get Free Report) and Akebia Therapeutics (NASDAQ: AKBA - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast t
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 01'st Dec 2025
CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
Q32 Bio Sells Complement Inhibitor ADX-097
07:00am, Monday, 01'st Dec 2025
-- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata -- -- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash ru
Akebia Announces Establishment of Rare Kidney Disease Pipeline
07:00am, Monday, 01'st Dec 2025
Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease ind
Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
08:00am, Monday, 24'th Nov 2025
CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,
Acadian Asset Management LLC Takes Position in Akebia Therapeutics, Inc. $AKBA
03:15am, Friday, 14'th Nov 2025
Acadian Asset Management LLC acquired a new position in shares of Akebia Therapeutics, Inc. (NASDAQ: AKBA) in the undefined quarter, according to the company in its most recent disclosure with the Sec
Akebia Therapeutics (AKBA) Loses 39.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:35am, Tuesday, 11'th Nov 2025
The heavy selling pressure might have exhausted for Akebia Therapeutics (AKBA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street
Akebia Therapeutics, Inc. (AKBA) Q3 2025 Earnings Call Transcript
11:01am, Monday, 10'th Nov 2025
Akebia Therapeutics, Inc. ( AKBA ) Q3 2025 Earnings Call November 10, 2025 8:00 AM EST Company Participants Mercedes Carrasco - Senior Director of Investor & Corporate Communications John Butler - CEO
